SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-009643
Filing Date
2024-07-01
Accepted
2024-07-01 16:20:13
Documents
16
Period of Report
2024-06-27
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ymab-20240627x8k.htm   iXBRL 8-K 61513
2 EX-10.1 ymab-20240627xex10d1.htm EX-10.1 93266
3 EX-99.1 ymab-20240627xex99d1.htm EX-99.1 17374
4 GRAPHIC ymab-20240627xex99d1002.jpg GRAPHIC 8634
  Complete submission text file 0001558370-24-009643.txt   338364

Data Files

Seq Description Document Type Size
5 EX-101.SCH ymab-20240627.xsd EX-101.SCH 3397
6 EX-101.LAB ymab-20240627_lab.xml EX-101.LAB 15924
7 EX-101.PRE ymab-20240627_pre.xml EX-101.PRE 10316
18 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20240627x8k_htm.xml XML 4845
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 241090888
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)